Skip to main content

Table 1 Baseline characteristics of the 35 participants who completed the study

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

 

All (n = 35)

Walk (n = 21)

Strength-Walk (n = 14)

Demographic and general characteristics

 Male gendera

26 (74%)

12 (57%)a

14 (100%)a

 Age (years, median, Q1-Q3)

48 (44–54)

48 (43–54)

49 (44–54)

 Caucasian race

35 (100%)

21 (100%)

14 (100%)

 BMI (Kg/m2)

25.6 (22.2-27.2)

25.3 (21.6-27.5)

25.8 (24.1-26.9)

Risk Group

 Ex-intravenous drug users

8 (23%)

7 (33%)

1 (7%)

 Men-having-sex-with-men

21 (57%)

7 (33%)

13 (93%)

 Heterosexual infection

6 (17%)

6 (29%)

0

 Vertical infection

1 (3%)

1 (5%)

0

HIV infection variables

 Previous AIDS-defining events

9 (25%)

7 (33%)

2 (14%)

 Nadir CD4+ T-cells/μL (median, Q1-Q3)

94 (37–197)

80 (34–140)

188 (77–258)

 Current CD4+ T-cells/μL (median, Q1-Q3)

577 (406–726)

485 (374–686)

624 (527–740)

 VL < 40 c/mL

34 (97%)

21 (100%)

13 (93%)

 Hepatitis C virus coinfection

4 (11%)

4 (19%)

0

 VACS Index

12 (5–19)

16 (6–24)

9 (0–12)

Smoking and Treatments

 Smokers

8 (23%)

6 (29%)

2 (14%)

 2NRTI + Protease inhibitor

14 (40%)

7 (33%)

7 (50%)

 2NRTI + NNRTI

11 (31%)

7 (33%)

4 (29%)

 Other ART regimens

10 (28%)

7 (33%)

3 (21%)

 Beta blockersb

6 (17%)

5 (24%)

1 (7%)

 Other anti-hypertensive drugsb

5 (14%)

2 (10%)

3 (21%)

 Statinsb

10 (29%)

4 (19%)

6 (42%)

 Fibratesb

2 (6%)

0

2 (14%)

Inclusion Criteria

 Lipodystrophy

35 (100%)

21 (100%)

14 (100%)

  ≥ 1 metabolic syndrome criterion

32 (91%)

19 (90%)

13 (93%)

 Blood triglycerides ≥150 mg/dL

14 (40%)

8 (38%)

6 (42%)

 Blood HDL-C ≤40 (m) or ≤50 (w) mg/dL

12 (34%)

9 (43%)

3 (21%)

 Blood glucose ≥110 mg/dL

1 (3%)

0

1 (7%)

 Waist ≥102 (m) or ≥88 (w) cm

10 (28%)

8 (38%)

2 (14%)

 SBP ≥150 or DBP ≥85 mmHg

12 (34%)

7 (33%)

5 (36%)

  1. Values are expressed as number of patients (%) where no otherwise indicated
  2. aWalk vs. strength-walk, p = 0.005
  3. bChronic treatment, with no changes during the training period or the 6 weeks before training
  4. VACS Veterans Ageing Cohort Study, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, m men, w women, SBP systolic blood pressure, DBP, diastolic blood pressure